Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ - Fierce Biotech

What the report says

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to earth with a damaging phase 3 flop. | Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has bee…